REPLIGEN ($RGEN) posted quarterly earnings results for Q3 2026 on Tuesday, October 27th. The company reported earnings of $0.53 per share, beating estimates of $0.47 by $0.06. The company also reported revenue of $209,310,000, missing estimates of $210,751,716 by $-1,441,716.
You can see Quiver Quantitative's $RGEN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
REPLIGEN Insider Trading Activity
REPLIGEN insiders have traded $RGEN stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:
- OLIVIER LOEILLOT (Chief Executive Officer) has made 0 purchases and 5 sales selling 19,422 shares for an estimated $3,493,520.
- JASON K GARLAND (CFO) sold 530 shares for an estimated $79,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
REPLIGEN Hedge Fund Activity
We have seen 260 institutional investors add shares of REPLIGEN stock to their portfolio, and 206 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 3,125,867 shares (-64.1%) from their portfolio in Q2 2026, for an estimated $426,493,293
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,368,231 shares (+3153.5%) to their portfolio in Q2 2026, for an estimated $186,681,437
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 788,571 shares (+inf%) to their portfolio in Q2 2026, for an estimated $107,592,627
- WASATCH ADVISORS LP removed 683,092 shares (-43.0%) from their portfolio in Q3 2026, for an estimated $131,310,775
- AMERIPRISE FINANCIAL INC added 650,918 shares (+70.4%) to their portfolio in Q2 2026, for an estimated $88,811,251
- BLACKROCK, INC. removed 608,116 shares (-10.1%) from their portfolio in Q2 2026, for an estimated $82,971,347
- HOLOCENE ADVISORS, LP added 583,302 shares (+82.3%) to their portfolio in Q2 2026, for an estimated $79,585,724
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
REPLIGEN Analyst Ratings
Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 05/06/2026
To track analyst ratings and price targets for REPLIGEN, check out Quiver Quantitative's $RGEN forecast page.
REPLIGEN Price Targets
Multiple analysts have issued price targets for $RGEN recently. We have seen 7 analysts offer price targets for $RGEN in the last 6 months, with a median target of $160.0.
Here are some recent targets:
- Robert Wasserman from Benchmark set a target price of $185.0 on 07/07/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $160.0 on 07/06/2026
- Sidharth Sahoo from HSBC set a target price of $150.0 on 06/03/2026
- Mike Polark from Wolfe Research set a target price of $145.0 on 06/02/2026
- Dan Leonard from RBC Capital set a target price of $160.0 on 05/15/2026
- Luke Sergott from Barclays set a target price of $160.0 on 05/06/2026
- Casey Woodring from JP Morgan set a target price of $165.0 on 05/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
